Page last updated: 2024-08-23

phorbol 12,13-dibutyrate and rosiglitazone

phorbol 12,13-dibutyrate has been researched along with rosiglitazone in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bosco, AA; Mattos, RT; Nogueira-Machado, JA	1

Other Studies

1 other study(ies) available for phorbol 12,13-dibutyrate and rosiglitazone

Article	Year
Rosiglitazone, a PPAR-γ agonist, inhibits VEGF secretion by peripheral blood mononuclear cells and ROS production by human leukocytes. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2012, Volume: 61, Issue:1 Topics: Adult; Humans; Hypoglycemic Agents; Leukocytes; Leukocytes, Mononuclear; Luminescence; Middle Aged; Naphthalenes; Phorbol 12,13-Dibutyrate; PPAR gamma; Protein Kinase C; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones; Vascular Endothelial Growth Factor A	2012

Article

Year

Rosiglitazone, a PPAR-γ agonist, inhibits VEGF secretion by peripheral blood mononuclear cells and ROS production by human leukocytes.

Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2012, Volume: 61, Issue:1

Topics: Adult; Humans; Hypoglycemic Agents; Leukocytes; Leukocytes, Mononuclear; Luminescence; Middle Aged; Naphthalenes; Phorbol 12,13-Dibutyrate; PPAR gamma; Protein Kinase C; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones; Vascular Endothelial Growth Factor A

2012